March 26, 2025
CompagOs on Supertrends: Bioprinted Bone ModelsTranslational diagnostics
From functional bone mechanobiology to earlier insight
CompagOs is advancing translational research that links functional bone mechanobiology to future diagnostic pathways, with the aim of supporting earlier insight into bone metastases and skeletal complications in cancer patients.
We believe the future of biomedical research and diagnostics will move beyond single-target readouts or isolated single-timepoint snapshot measurements. Biohardware complements these approaches by enabling the study of living human systems over time, revealing functional behavior rather than static measurements. CompagOs is building that future for bone health.
Not available for diagnostic use. Not for clinical decision-making.
Clinical need
Clinical need
Bone metastases and therapy-induced bone loss often progress without early symptoms. Structural damage and clinical complications may therefore occur before changes are detected by current imaging-based workflows.
Understanding the underlying biology of bone remodeling is critical for translational research exploring future diagnostic pathways. CompagOs focuses on functional bone biology to investigate how earlier biological changes may precede radiographic findings.
16.4M
5-year prevalence
People living with breast, prostate, or lung cancer worldwide1
30–70%
bone metastases
Patients who develop bone metastases, depending on tumor type and stage2
Up to 55%
skeletal-related events
Patients with bone metastases who experience skeletal-related events3
~2×
direct medical costs
Higher annual direct medical costs reported in metastatic bone disease4
Focus
Lung cancer first
A high-burden disease setting with an urgent need for earlier biological insight into skeletal complications.
CompagOs’s current translational research focuses on lung cancer–associated skeletal complications, where bone involvement is common and clinical need remains high. Using the Bon3OID biohardware platform, these programs investigate how patient-derived blood cells interact with human bone-like tissue constructs to reveal functional signals of bone mechanobiology and remodeling. In disease settings where skeletal complications can arise early, this approach enables the study of biological propensity toward bone resorption before clinical consequences occur, supporting translational research aimed at earlier insight into disease progression.
Updates
Progress and announcements
- IARC / WHO. GLOBOCAN 2022: five-year prevalence (both sexes), worldwide (breast, prostate, and trachea/bronchus/lung). Online database. Accessed December 2025.
- Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity.Clinical Cancer Research. 2006;12(20 Pt 2):6243s–6249s.
- Cetin K, Christiansen CF, Jacobsen JB, et al. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study.Lung Cancer. 2014;86(2):247–254.
- Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S.Cancer. 2007;109(11):2334–2342.
Not available for diagnostic use. Not for clinical decision-making.